lilly glp-1 drug FDA approves Foundayo, an oral alternative to Wegovy and Ozempic A GLP-1 Pill May Help

however, they can also lead to nutrient depletion

This paper explores the intricate connection ...

Online health startup Ro is getting into weight loss medicine, offering patients the trending obesity and diabetes GLP-1 class of drugs and real-time tracking.

Using a global dataset and propensity matching, they found significantly lower mortality rates, major cardiovascular events (MACEs), and adverse kidney outcomes (MAKEs) among GLP-1 RA users compared to non-users

GLP-1 drugs like semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and orforglipron (Foundayo) offer promising results for weight loss and health.

Current expectations point to FDA review and potential approval in the 2027 to 2028 range